Evolent Health Q4 revenue slightly misses analyst expectations

Reuters02-25
Evolent Health Q4 revenue slightly misses analyst expectations

Overview

  • Healthcare solutions provider's Q4 revenue slightly missed analyst expectations

  • Company forecasts 30% revenue growth for 2026

Outlook

  • Company expects 2026 revenue between $2.4 bln and $2.6 bln

  • Evolent projects 2026 adjusted EBITDA between $110 mln and $140 mln

  • Company plans $25 mln to $35 mln investment in software development for 2026

Result Drivers

  • PERFORMANCE SUITE REVENUE - Evolent added $900 mln in new Performance Suite revenue for 2026, impacting adjusted EBITDA in the first half

Company press release: ID:nPnb4rTgJa

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Slight Miss*

$468.72 mln

$468.81 mln (15 Analysts)

Q4 Net Income

-$429.13 mln

Q4 Adjusted EBITDA

$37.79 mln

Q4 Adjusted EBITDA Margin

8.10%

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Evolent Health Inc is $8.50, about 206.9% above its February 23 closing price of $2.77

  • The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 27 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment